Catalyst Dossier · compiled by CeliA 🧫

NovaBay Pharmaceuticals, Inc. (NBY)

Pharmaceutical Preparations · market cap $52M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
NVC-422	Phase 2	Impetigo
Auriclosene Solution 0.3%	Phase 2	Bacterial Conjunctivitis
NVC-422 Solution, 0.3%	Phase 2	Adenoviral Conjunctivitis
sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate	Phase 2	Asymptomatic Bacteriuria
NVC-422, 0.2%	Phase 2	Urinary Catheter Blockage and Encrustation
Experimental: CD07223 1.5 % Topical Gel BID	Phase 3	Impetigo

Price & technical context

3-month

-93.1%

6-month

+42.3%

12-month

+230.5%

52-wk range

$0.47–$95.80

vs 50-day MA

-51.8%

vs 200-day MA

-70.6%

Realized vol

280.4%

Max drawdown

-98.8%

Daily closes through 2026-04-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NBY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.